A5046594003- Mechanical Circulatory Support Devices
- Transplantation: Methods and Outcomes
- Xenotransplantation and immune response
- Organ Transplantation Techniques and Outcomes
- Respiratory Support and Mechanisms
- Venous Thromboembolism Diagnosis and Management
- Cardiac Structural Anomalies and Repair
- Cardiac Arrest and Resuscitation
- Atrial Fibrillation Management and Outcomes
- Intensive Care Unit Cognitive Disorders
- Central Venous Catheters and Hemodialysis
- Aortic Disease and Treatment Approaches
- COVID-19 Clinical Research Studies
- Aortic aneurysm repair treatments
- Renal Transplantation Outcomes and Treatments
- Heart Failure Treatment and Management
- Immune Response and Inflammation
- Virus-based gene therapy research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Infectious Aortic and Vascular Conditions
- Cardiac Valve Diseases and Treatments
- Animal Genetics and Reproduction
- Viral Infections and Immunology Research
- T-cell and B-cell Immunology
- Long-Term Effects of COVID-19
University of Maryland, Baltimore
2014-2024
UCLouvain
2023
Hudson Institute
2023
VA Maryland Health Care System
2018-2023
University of Fribourg
2023
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
2023
The University of Sydney
2023
University of Maryland Medical Center
2020
University of Maryland, College Park
2016
University of Baltimore
2016
With the increased demand for veno-venous extracorporeal membrane oxygenation (VV ECMO) during COVID-19 pandemic, guidelines patient candidacy have often limited this modality patients with a body mass index (BMI) less than 40 kg/m2. We hypothesize that VV ECMO at least class III obesity (BMI ≥ 40) decreased in-hospital mortality when compared to non-COVID-19 and non-class obese populations.This is single-center retrospective study of from January 1, 2014, November 30, 2021. Our institution...
Specific blockade of T cell costimulation pathway is a promising immunomodulatory approach being developed to replace our current clinical immunosuppression therapies. The goal this study compare results associated with 3 monoclonal antibodies directed against the CD40/CD154 pathway.
Abstract Background Elevated pulmonary vascular resistance ( PVR ), platelet adhesion, coagulation activation, and inflammation are prominent features of xenolung rejection. Here, we evaluate the role thromboxane histamine on , their contribution to other lung xenograft injury mechanisms. Methods Gal TKO . hCD 46 single pig lungs were perfused ex vivo with fresh heparinized human blood: either treated 1‐Benzylimidazole (1‐ BIA ) combined receptor blocker famotidine (n = 4) or diphenhydramine...
Abstract Background The mortality benefit of VV-ECMO in ARDS has been extensively studied, but the impact on long-term functional outcomes survivors is poorly defined. We aimed to assess association between ECMO and a contemporaneous cohort ARDS. Methods Multicenter retrospective study who presented follow-up clinic. primary outcome was FVC% predicted. Univariate multivariate regression models were used evaluate outcome. Results This enrolled 110 ARDS, 34 whom managed using ECMO. younger (35...
Selective CD28 inhibition is actively pursued as an alternative to B7 blockade using cytotoxic T lymphocyte antigen 4 Ig based on the hypothesis that checkpoint immune regulators and programmed death ligand 1 will induce tolerogenic signals. We previously showed blocking a monovalent nonactivating reagent (single-chain anti-CD28 Fv fragment linked alpha-1 antitrypsin [sc28AT]) synergizes with calcineurin inhibitors in nonhuman primate (NHP) kidney heart transplantation. Here, we explored...
Introduction Massive pulmonary embolism (MPE) is a rare but highly fatal condition. Our study’s objective was to evaluate the association between advanced interventions and survival among patients with MPE treated venoarterial extracorporeal membrane oxygenation (VA-ECMO). Methods This retrospective review of Extracorporeal Life Support Organization (ELSO) registry data. We included adult who were VA-ECMO during 2010–2020. Primary outcome hospital discharge; secondary outcomes ECMO duration...
Abstract Thrombomodulin is important for the production of activated protein C (APC), a molecule with significant regulatory roles in coagulation and inflammation. To address known molecular incompatibilities between pig thrombomodulin human thrombin that affect conversion into APC, GalTKO.hCD46 pigs have been genetically modified to express (hTBM). The aim this study was evaluate impact transgenic hTBM expression on dysregulation observed association lung xenograft injury an established...
Background: The most critically ill patients with coronavirus disease 2019 (COVID-19) may require advanced support modalities, such as veno-venous extracorporeal membrane oxygenation (VV-ECMO). A systematic, methodical approach to a respiratory pandemic on state and institutional level is critical. Methods: We conducted retrospective review of our response the COVID-19 pandemic, focusing creation dedicated airlock biocontainment unit (BCU) treat refractory acute distress syndrome (CARDS)....
(1) Background: COVID-19 acute respiratory distress syndrome (CARDS) has several distinctions from traditional (ARDS); however, patients with refractory failure may still benefit veno-venous extracorporeal membrane oxygenation (VV-ECMO) support. We report our challenges caring for CARDS on VV-ECMO and alterations to management strategies. (2) Methods: conducted a retrospective review of institutional strategies managing who required in dedicated airlock biocontainment unit (BCU), March June...
Abstract Background As the pandemic progressed, use of extracorporeal membrane oxygenation (ECMO) for COVID‐19‐related acute respiratory distress syndrome increased, and patient triage transfer to ECMO centers became important optimize outcomes. Our objectives are identify predictors veno‐venous (V‐V ECMO) evaluation as well describe outcomes accepted patients. Methods This is a single‐center, retrospective analysis V‐V requests adult patients with known or suspected COVID‐19 failure from...
Abstract Introduction Expression of human complement pathway regulatory proteins (hCPRP's) such as CD46 or CD55 has been associated with improved survival pig organ xenografts in multiple different models. Here we evaluate the hypothesis that an increased gene dose, through homozygosity additional expression a second hCPRP, is protein and protection from injury when GTKO lung are perfused blood. Methods Twenty three lungs heterozygous for (GTKO.heteroCD46), 10 homozygous hCD46...
Introduction: Pregnancy in patients with advanced heart failure requiring left ventricular assist device (LVAD) support is risky and discouraged, though there are cases of successful deliveries. Hypothesis: A 29-year-old G3P2002 female history embolic cerebrovascular accident, postpartum hemorrhage, peripartum cardiomyopathy status-post HeartMate 3 (HM3) LVAD, became pregnant after intrauterine dislodgement. She elected to continue the pregnancy against advice maternal-fetal medicine (MFM)....
It remains unclear whether patients who will not accept allogeneic blood transfusion can be managed successfully with veno-arterial (V-A) extracorporeal membrane oxygenation (ECMO). The objective of our study was to determine what percentage V-A ECMO were without transfusion.This a retrospective, observational cohort cardiogenic shock requiring between January 2016 and 2019. primary outcome avoidance any transfusion.Of the 206 included, 23 (11.2%) transfusion. Fourteen (60.9%) avoided during...
The PREdiction of Survival on ECMO Therapy Score (PRESET-Score) predicts mortality while veno-venous extracorporeal membrane oxygenation (VV ECMO) for acute respiratory distress syndrome. aim our study was to assess the association between PRESET-Score and survival in a large COVID-19 VV cohort.This single-center retrospective patients from 15 March 2020, 30 November 2021. Univariable Multivariable analyses were performed patient score differences.A total 105 included analysis with mean...
Abstract Selective CD28 blockade, which preserves CTLA-4-dependent immune regulation, is a promising approach to induce tolerance. FR104, novel antagonist, was evaluated in monkey heart transplant recipients that received αCD28 alone (n=3, FR104) or combination with αCD154 (n=5, hu5C8), dosed achieve receptor coverage for 84 days; results were compared (n=4). Acute (AR) and chronic (CAV) rejection scores quantified histologically. Median graft survival time (MST) FR104 (167d), hu5C8 (133d),...